Reneuron Share Discussion Threads

[abid6814] 11/2/2022 14:58

Richard Griffiths adding again

[john henry] 11/2/2022 14:57

Reason for rise is seller on fumes imho

[martinfrench] 11/2/2022 14:54

ceo leaves and share price up 17%, think thats all the feed back he needs

awful ceo, no commerciality

[jpuff] 11/2/2022 14:48

Obviously great news that the ceo has walked. Onwards and upwards from here

[haggismchaggis] 11/2/2022 14:21

Looks like 2022 is still mainly going to be about the data, as they can't conjure up much else can they, trials have to run their course, there are no shortcuts?

[lovewinshatelosses] 11/2/2022 12:16

This was the correct move, IMO. We will have to wait and see whether this company is going to be successful in the new direction it has decided to take, but thus far Iain and Catherine should give holders some confidence. I am reasonably impressed so far.
Not buying any more unless they buy a decent slug on the open market themselves though! GLA.

[bradders51] 11/2/2022 11:42

That's a more realistic price action.
Let's hope it continues. GLA

[bradders51] 11/2/2022 09:48

Onceaday: Yes they do and it's being tested now.
What you mean is that they haven't got a product to market. Very different thing.

[onceaday] 11/2/2022 09:19

More like a final sunset! £200m of investor funds burned through and they still have no product.

[fred177] 11/2/2022 09:07

The way Katherine Isted interjected with regards to licensing deals being done shows she has a lot more PR commercial nous than Olav who was waffling on saying this year is all about the data, no great surprise he's gone, Katherine was very impressive, to have an accountant with a scientific background must help IMHO

[bradders51] 11/2/2022 08:36

That's why the wry smile on Olav's face when asked about director buying.
Olav has come under a lot of criticism for the underperformance of this company, not just the failed RP trials.
Another new dawn ??

[bradders51] 11/2/2022 08:32

Olav forced out by the new more commercial/hard-headed directors.
Ian & Catherine are there to get the exosomes to market and then sell the whole company.

[ken chung] 11/2/2022 07:10

CEO getting out.Sub 5p coming.Lemmings and mushrooms only.

[bigbigdave] 11/2/2022 07:08

Director Change

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Olav Hellebø is standing down as CEO and executive director of the Company and will leave the Company on 28 February 2022.

With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.

Olav Hellebø, commented : "Following ReNeuron's recent change in strategy, the time has come for me to pursue other opportunities. I would like to thank employees and other stakeholders who have been instrumental in pursuing our pioneering technologies over many years."

Iain Ross, Chairman of ReNeuron, commented: " On behalf of the Board and Management I would like to recognise Olav's contribution to the Company over the last 7 years and wish him well in the future."

[onceaday] 10/2/2022 10:53

More selling by Obotritia.

[whatno] 09/2/2022 16:02

Given that one of the directors is chairman of Obotritia, that seems unlikely.

[bradders51] 09/2/2022 15:46

I've had a few but not enough for anyone to notice. (one day Rodney) :-))

[lovewinshatelosses] 09/2/2022 14:13

Who is buying them though? Not the directors, obviously, although perhaps they will be loading up as soon as they are outside of the closed period. They had better do so, if they want to demonstrate to the market that they are not simply pay cheque merchants :)

[whatno] 09/2/2022 12:58

Obotritia seem to be selling more. I am guessing they have decided to exit based on the hRPC prospect.

[bradders51] 08/2/2022 11:14

I suppose a few ophthalmologists have to go now that we have no use for them.

[onceaday] 08/2/2022 10:58

Looks like their CMO has departed.. hxxps://investors.adverum.com/news/news-details/2022/Adverum-Biotechnologies-Appoints-Richard-Beckman-M.D.-as-Chief-Medical-Officer/default.aspx

[bradders51] 08/2/2022 10:13

If there is a cash call this year, I would imagine it much later on than the present.
The share price, and investor confidence, is too battered at the moment and anyway, they don't need the money yet.

Another 6 to 9 months and we should should know in what direction this company is going. If it's good, then the share price should recover enough to get a successful cash call away. If there's a licensing agreement signed this year, maybe we can get away without one.

[onceaday] 08/2/2022 09:44

Another cash call can't be far away. Loss making CEOs invariably make noises about their cash runway being adequate just before springing a raise on unsuspecting investors - just as happenned last time around.

There is no independent scientific validation of anything here. We have no idea of their competence - when was the last time the company published in a reputable scientific journal?

Look back at the last 10 years of presentations on youtube.. It's always the same messaging.

[bradders51] 08/2/2022 08:23

So how do they develop the Exosome programme and products without spending?
What do you want them to do. Just sit there hoping and praying?